SCHEMBL574934

SCHEMBL574934

CCCCOC(=O)N1CC[CH]CC1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.63
POLB P06746 2/20 0.63
LMNA P02545 1/20 0.63
HRH2 P25021 6/20 0.46
HRH1 P35367 6/20 0.46
ALDH1A1 P00352 5/20 0.44
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ATM Q13315 1/20 0.41
BCHE P06276 1/20 0.41
TSHR P16473 3/20 0.41
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
HPGD P15428 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856186 0.90 SMN1; SMN2 (0.55) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL1713157 0.89 POLB (0.49) SMN1; SMN2POLBLMNAALDH1A1TDP1
SCHEMBL9405372 0.87 POLB (0.73) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL11120122 0.85 LMNA (0.50) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL3634052 0.83 SMN1; SMN2 (0.69) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL1859157 0.83 SMN1; SMN2 (0.69) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL1713425 0.83 SMN1; SMN2 (0.44) SMN1; SMN2POLBLMNAALDH1A1TDP1
SCHEMBL293394 0.83 TSHR (0.57) SMN1; SMN2POLBLMNAALDH1A1TDP1
SCHEMBL15820038 0.82 SMN1; SMN2 (0.55) SMN1; SMN2POLBLMNAHRH2HRH1
SCHEMBL1826048 0.81 SMN1; SMN2 (0.67) SMN1; SMN2POLBLMNAHRH2HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105102446-A Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS INC 2015-11-25 CN claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
WO-2011025541-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. (US) 2011-03-03 WO claimed
WO-2006137658-A1 NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONGBU HITEK CO., LTD. (KR) 2006-12-28 WO claimed
EP-1196411-A1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA, INC. (US) 2002-04-17 EP claimed
WO-2001005783-A1 BRADYKININ B1 RECEPTOR ANTAGONISTS PHARMACOPEIA, INC. (US) 2001-01-25 WO claimed
EP-3259269-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2017-12-27 EP disclosed
WO-2016134320-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2016-08-25 WO disclosed
EP-3030560-A1 BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS Actelion Pharmaceuticals Ltd (CH) 2016-06-15 EP disclosed
CN-105102446-A Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS INC 2015-11-25 CN disclosed
WO-2015019325-A1 BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2015-02-12 WO disclosed
EP-2678336-A1 THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2014-01-01 EP disclosed
EP-2601185-A1 DERIVATIVES OF PYRAZOLOPHENYL-BENZENESULFONAMIDE COMPOUNDS AND USE THEREOF AS ANTITUMOR AGENTS Nerviano Medical Sciences S.r.l. (IT) 2013-06-12 EP disclosed
WO-2006137658-A1 NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONGBU HITEK CO., LTD. (KR) 2006-12-28 WO disclosed
EP-1648868-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS Celltech R & D Limited (GB) 2006-04-26 EP disclosed
WO-2004113298-A1 HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS CELLTECH R & D LIMITED (GB) 2004-12-29 WO disclosed
CN-1423647-A Beta-alanine derivatives and their use as receptor antagonists FUJISAWA PHARMACEUTICAL CO (JP) 2003-06-11 CN disclosed
EP-1268412-A1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 2003-01-02 EP disclosed
WO-2001070677-A1 SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 2001-09-27 WO disclosed
WO-1996002514-A1 UREA AND CARBAMIC ACID DERIVATIVES, DRUGS CONTAINING THESE COMPOUNDS, AND PROCESS FOR THEIR PREPARATION DR. KARL THOMAE GMBH (DE) 1996-02-01 WO disclosed